Funder
National Institutes of Health
Subject
Organic Chemistry,Drug Discovery,Pharmacology,General Medicine
Reference38 articles.
1. MEK genomics in development and disease;Bromberg-White;Brief Funct Genomics,2012
2. MEK and PI3K inhibition in solid tumors: rationale and evidence to date;Jokinen;Ther Adv Med Oncol,2015
3. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging;Steelman;Aging (N Y),2011
4. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer;Saini;Cancer Treat Rev.,2013
5. Targeting alterations in the RAF-MEK pathway;Yaeger;Cancer Discov.,2019
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Benzimidazole‐Containing Compounds as Anticancer Agents;ChemistrySelect;2024-08-22
2. Design, synthesis and antitumor effects of novel benzimidazole derivatives as PI3K inhibitors;Bioorganic & Medicinal Chemistry Letters;2023-10
3. Antitumor Activity of s-Triazine Derivatives: A Systematic Review;Molecules;2023-05-23
4. Recent updates on 1,2,3‐, 1,2,4‐, and 1,3,5‐triazine hybrids (2017–present): The anticancer activity, structure–activity relationships, and mechanisms of action;Archiv der Pharmazie;2022-11-13
5. Discovery of Novel PI3Kδ Inhibitors Based on the p110δ Crystal Structure;Molecules;2022-09-21